![Cells | Free Full-Text | Boosting the Immune Response—Combining Local and Immune Therapy for Prostate Cancer Treatment | HTML Cells | Free Full-Text | Boosting the Immune Response—Combining Local and Immune Therapy for Prostate Cancer Treatment | HTML](https://www.mdpi.com/cells/cells-11-02793/article_deploy/html/images/cells-11-02793-g001.png)
Cells | Free Full-Text | Boosting the Immune Response—Combining Local and Immune Therapy for Prostate Cancer Treatment | HTML
BETH CHACHOUA (ISSY-LES-MOULINEAUX) Chiffre d'affaires, résultat, bilans sur SOCIETE.COM - 491002697
![Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors - Annals of Oncology Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/d5524b1f-7071-4ac5-910c-ffc6fab16d7f/gr1_lrg.jpg)
Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors - Annals of Oncology
![Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours - European Journal of Cancer Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours - European Journal of Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/79549895-0c20-48d6-b386-5a10bec34a42/gr1_lrg.jpg)
Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours - European Journal of Cancer
![Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors | British Journal of Cancer Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors | British Journal of Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fsj.bjc.6601550/MediaObjects/41416_2004_Article_BF6601550_Fig1_HTML.jpg)